期刊论文

中文

吉林中医药

1003-5699

2020

40

4

505-509

10.13463/j.cnki.jlzyy.2020.04.025

81603603:国家自然科学基金 2016SK2051:湖南省科技计划 201803:湖南省中医药管理局重点课题

本校为第一机构

目的 探讨益气化瘀解毒方干预后对Sorafenib获得性耐药人肝癌QGY7702细胞(QGY7702/Sora)增殖及MRP、GST-π和Topo Ⅱ 基因表达的影响.方法 培养QGY7702/Sora细胞和QGY7702细胞,利用Cell Counting Kit-8(CCK-8)法检测Sorafenib对细胞的半数抑制率浓度(IC50值),计算耐药指数RI;观察益气化瘀解毒方对耐药细胞的增殖影响;采用荧光定量PCR检测药物干预前后2种细胞中MRP、GST-π和Topo Ⅱ基因表达水平.结果 亲本细胞和耐药细胞Sorafenib的IC50值分别为(7.993±0.522) μmol/L和(19.651±1.216) μmol/L,RI约为2.5.益气化瘀解毒方可抑制耐药细胞的增殖活性.2种细胞的MRP、GST-π、Topo Ⅱ表达量无明显差...

Objective To explore the effect of Yiqi Huayu Jiedu Prescription on the proliferation and expressionof MRP,GST-π and Topo II genes of sorafenib acquired drug-resistant human hepatocarcinoma QGY7702 cells (QGY7702/Sora).Methods QGY7702/Sora cells and QGY7702 cells were cultured.Cell Counting Kit-8 (CCK-8) method was used to detect the half inhibition rate (IC50) of Sorafenib on cells and calculate the resistance indexRI.To observe the effect of Yiqi Huayu Jiedu prescription on the proliferation of drug-resistant cells,and to detectthe expressio...